A Phase 1, First-in-human Study of the Safety, Single- and Multiple-Dose Pharmacokinetics, and Preliminary Activity of Escalating Doses of RBN-2397, an Oral PARP7 Inhibitor, in Patients with Solid Tumors

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Eligibility

enrolling to Expansion cohorts only: SCCL, HNSCC, HR+ breast cancer, and PARP7 amplified cancer.

Type of Study

Treatment

Locations

University of Colorado Hospital

Principal Investigator
Photograph of Erin Schenk,  MD, PhD

Erin Schenk, MD, PhD

Study ID

Protocol Number: 21-3286

More information available at ClinicalTrials.gov: NCT04053673

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers